About US
Contact us
-
AstraZeneca and Bristol-Myers Squibb announce EU approval for diabetes drug XigduoThe European Commission has granted marketing authorisation to AstraZeneca and Bristol-Myers Squibb's (BMS's) Xigduo (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1,000mg tablets) fo2014/1/28
-
FDA grants orphan drug status to BioLineRx's BL-8040 for stem cell mobilisation treatmentIsrael-based clinical-stage biopharmaceutical firm BioLineRx has received notice from the US Food & Drug Administration (FDA) confirming an Orphan Drug Designation for BL-8040 as a treatment for s2014/1/27
-
MIP Technologies AB Presents a New Range of Polymeric Separation Resins for Industrial UseMIP Technologies (a subsidiary of Biotage AB), a leading global supplier of solutions and technologies for specialty polymeric separation materials, is pleased to present a new range of RENSA industri2014/1/27
-
Bayer launches takeover offer for all shares of Algeta for €2.1bnBayer Nordic's subsidiary Aviator Acquisition has started the voluntary cash offer to acquire all the shares of Norwegian oncology firm Algeta for Nkr362 per share. The total value of the transaction2014/1/24
-
UK research institutions and Nuevolution collaborate on cancer drug discoveryUK's Institute of Cancer Research (ICR) and Cancer Research Technology (CRT) have entered into a drug discovery collaboration with Denmark-based Nuevolution to identify novel lead candidates for treat2014/1/24
-
Santhera's Raxone gets French temporary approval for treatment of Leber's hereditary optic neuropathySwitzerland-based Santhera Pharmaceuticals has received 'Autorisation Temporaire d'Utilisation dite de cohorte' (cohort ATU), a temporary authorisation, from the French National Agency for Medicines a2014/1/23
-
Bladder Cancer Market to Witness Moderate Growth by 2017, Despite Anticipate​d Launch of EOquinThe bladder cancer therapeutics market in the six major countries (6MM) — the US, France, Germany, Italy, Spain and UK — is forecast to climb from $239.3 million in 2012 to $297.5 million by 2017, at2014/1/23
-
Aegerion's Juxtapid capsules approved for treatment of HoFH patients in MexicoThe Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) has approved Aegerion Pharmaceuticals' Juxtapid (lomitapide) capsules for the treatment of homozygous familial hyperc2014/1/22
-
2D Barcode Scanner for Frozen SamplesMicronic, specialists in traceable sample storage solutions, has announced a further addition to its popular ‘blue-white’ Tracxer Code Reader line. The Tracxer Code Reader RD235 CRYO offers a high-2014/1/22
-
Horizon Discovery and Transgenomic Announce Collaboration for Validation Control and Development of Genetic Diagnostic TestsHorizon Discovery Ltd, a leading provider of research tools to support translational genomics and the development of personalised medicines, and Transgenomic, Inc., a global biotechnology company adva2014/1/21